 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...111112113114115116117118119120121...858859» |
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal: Tezepelumab: a new option for the treatment of severe asthma (Pubmed Central) - Nov 27, 2023
Therefore, in this review, we will show the clinical efficacy of tezepelumab in reducing the annual rate of exacerbations, improving lung function, and reducing bronchial hyperreactivity, regardless of the patient's baseline biomarker levels. Therefore, this new molecule is a highly effective therapeutic option for patients with severe asthma.
- | rocatinlimab (KHK4083) / Kyowa Kirin, Amgen
Journal: Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply. (Pubmed Central) - Nov 27, 2023
Therefore, this new molecule is a highly effective therapeutic option for patients with severe asthma. No abstract available
- || Stivarga (regorafenib) / Bayer
Clinical, P2 data, Journal: Zinc supplementation decreased incidence of grade (Pubmed Central) - Nov 27, 2023
P2
Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1-3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal cancer (mCRC) but commonly causes HFSR. This phase II randomized trial aimed to investigate whether zinc supplementation can reduce the severity of HFSR induced by regorafenib within the first 8 weeks of treatment (NCT03898102).
- ||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis (clinicaltrials.gov) - Nov 27, 2023
P3, N=564, Completed, Sponsor: UCB Biopharma SRL
This phase II randomized trial aimed to investigate whether zinc supplementation can reduce the severity of HFSR induced by regorafenib within the first 8 weeks of treatment (NCT03898102). Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Vectibix (panitumumab) / Amgen, Takeda
Journal, Metastases: Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV. (Pubmed Central) - Nov 27, 2023
Active, not recruiting --> Completed Molecular hyperselection and comprehensive genomic profiling have a potential usefulness in elderly patients with
- || Stivarga (regorafenib) / Bayer
P2 data, Journal, Metastases: Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study. (Pubmed Central) - Nov 27, 2023
Responses were observed also in patients pretreated and refractory to another antiangiogenic agents. However, ORR and m-PFS were lower than reported with other antiangiogenics, and this was possibly due to discrepancies in the patient population and the high-rate of dose reductions.
- || barzolvolimab (CDX-0159) / Celldex, briquilimab (JSP191) / Jasper Therap, Xolair (omalizumab) / Roche, Novartis
Review, Journal: Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development. (Pubmed Central) - Nov 27, 2023
There is a clear need for additional approved treatment options beyond H1 receptor antagonists and the anti-IgE monoclonal antibody (mAb), omalizumab...The prolonged depletion of mast cells over several weeks by barzolvolimab could effectively control urticarial symptoms...However, long-term safety data beyond 12?weeks are still lacking. The outcome of ongoing or planned clinical trials with several anti-KIT mAbs will need to demonstrate benefits compared to anti-IgE in CU or whether one approach is better suited for specific urticaria endotypes.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Identification of Key Osteoporosis Genes Through Comparative Analysis of Men's and Women's Osteoblast Transcriptomes. (Pubmed Central) - Nov 27, 2023
Denosumab treatment in postmenopausal women down-regulated 6 key genes, up-regulated T cell proportions, and down-regulated fibroblast proportion...We identified 9 key osteoporosis genes by comparing the transcriptome of osteoblasts in women and men. Our findings' clinical implications were confirmed by multi-omics data and qRT-PCR, and our study provides novel biomarkers and therapeutic targets for osteoporosis diagnosis and treatment.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions. (Pubmed Central) - Nov 27, 2023
Periosteal reaction and sequestrum formation are suspected to be pre-clinical MRONJ lesions. Furthermore, ARD induced bony changes and radiographic variations between ARD types were seen.
- | briquilimab (JSP191) / Jasper Therap
Enrollment open: Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency (clinicaltrials.gov) - Nov 27, 2023
P2, N=32, Recruiting, Sponsor: National Cancer Institute (NCI)
Furthermore, ARD induced bony changes and radiographic variations between ARD types were seen. Not yet recruiting --> Recruiting
- ||| Ibrance (palbociclib) / Pfizer
Review, Journal, Adverse events, Metastases: Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. (Pubmed Central) - Nov 27, 2023
P4
Not yet recruiting --> Recruiting Exploratory safety analysis of PreCycle demonstrates for the first time in a randomized prospective trial that interactive autonomous eHealth-based support has a substantial favorable impact on the risk of SAEs and mitigates their severity for patients with advanced HR+/HER2- breast cancer on oral tumor therapy.
- | Wezlana (ustekinumab-auub) / Amgen
Journal: Analytical and Functional Similarity of the Biosimilar Candidate ABP (Pubmed Central) - Nov 27, 2023
Exploratory safety analysis of PreCycle demonstrates for the first time in a randomized prospective trial that interactive autonomous eHealth-based support has a substantial favorable impact on the risk of SAEs and mitigates their severity for patients with advanced HR+/HER2- breast cancer on oral tumor therapy. Based on a comprehensive similarity assessment, ABP
- ||| Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Retrospective data, Review, Journal, Adverse events: Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis. (Pubmed Central) - Nov 27, 2023
Aromatase inhibitors (AIs) as an upfront strategy (or as part of a switch strategy) have been added to the choice of Tamoxifen (T) alone...The switch strategy increases TE rate, whereas the addition of CDK4/6 to the standard AET was shown to significantly increase TE events. The results of the currently ongoing trials with CDK4/6 inhibitors will help obtain additional data to evaluate any differences among the different CDK4/6 inhibitors and clarify the weight of TE adverse events in the benefit/risk balance of this new adjuvant strategy.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis. (Pubmed Central) - Nov 27, 2023
Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT-associated harms between the BTT regimens evaluated.
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Mitigating transcriptional bottleneck using a constitutively active transcription factor, VP16-CREB, in mammalian cells. (Pubmed Central) - Nov 27, 2023
VP16-CREB was also used successfully with synthetic promoters containing cAMP response elements. Taken together, this strategy to introduce constitutively active TFs into cells is a useful means of overcoming the transcriptional limitations in recombinant mammalian cells.
- || Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Udenyca (pegfilgrastim-cbqv) / Coherus Biosci
PK/PD data, Journal: Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants. (Pubmed Central) - Nov 27, 2023
The bioequivalence of pegfilgrastim-cbqv administered using a prefilled AI and a PFS was established. The safety, including immunogenicity profiles, of pegfilgrastim-cbqv administered using the prefilled AI and the PFS were similar, with no new safety findings.
- || Review, Journal: Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review. (Pubmed Central) - Nov 27, 2023
The safety, including immunogenicity profiles, of pegfilgrastim-cbqv administered using the prefilled AI and the PFS were similar, with no new safety findings. In patients with allergic severe asthma and BECs of???260 cells/
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal, Real-world evidence, Real-world: PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study. (Pubmed Central) - Nov 27, 2023
In patients with allergic severe asthma and BECs of???260 cells/ Our results show that it can be reasonable to start palbociclib and ribociclib at reduced dose in patients aged ?75
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Journal: Aortitis after administration of pegfilgrastim to a healthy donor for peripheral blood stem cell collection. (Pubmed Central) - Nov 27, 2023
This is the first case report of pegfilgrastim-induced aortitis in an allo-PBSCT donor. Careful monitoring is warranted when administering pegfilgrastim to donors even without past medical history.
- | Blincyto (blinatumomab) / Astellas, Amgen
Biomarker, Journal, IO biomarker: Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia. (Pubmed Central) - Nov 27, 2023
P3
To examine this possibility, we conducted a post hoc analysis using data from the TOWER Clinical Trials (NCT02013167). Multivariate analysis showed that, along with the treatment groups, each of the following was independently correlated with superior progression-free survival: salvage-treatment phase, allogeneic stem cell transplantation, and pre-treatment ratio of bone marrow blasts-to-peripheral blood lymphocytes?<?25.
- || Review, Journal: The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies. (Pubmed Central) - Nov 27, 2023
Further research is needed to examine whether gene silencing therapy could improve clinical outcomes in patients with elevated LDL and/or Lp(a) levels. Confirmation of the tolerability and cost-effectiveness of long-term inhibition of PCSK9 and Lp(a) with this approach is essential.
- | Vectibix (panitumumab) / Amgen, Takeda
Journal: Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials. (Pubmed Central) - Nov 27, 2023
- | Tepezza (teprotumumab) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Journal: The key data from the 2022 European Thyroid Association congress: Toward personalized treatment of Graves' orbitopathy. (Pubmed Central) - Nov 27, 2023
Confirmation of the tolerability and cost-effectiveness of long-term inhibition of PCSK9 and Lp(a) with this approach is essential. No abstract available
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Combination of immunotherapy, radiotherapy and denosumab as the best approach even for NSCLC poor prognosis patients: a case report with strong response, prolonged survival and a review of literature. (Pubmed Central) - Nov 27, 2023
We analyzed our result comparing with currently published data about radio-immunotherapy or immunotherapy and BTT combination even though there is no published experience about integration of all 3 treatments. Approval studies often do not represent real-world experience (RWE), so we analyzed data from both RWE and clinical trials.
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Retrospective data, Journal: Impact of relative dose intensity of trabectedin with pegfilgrastim support: a single-centre retrospective study. (Pubmed Central) - Nov 27, 2023
Moreover, we found no association between patients receiving ?4 trabectedin cycles and the use of pegfilgrastim. These results suggested that trabectedin dose delays or reductions should be considered before administering prophylactic pegfilgrastim.
- || Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date: PARERE: PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (clinicaltrials.gov) - Nov 27, 2023
P2, N=214, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
These results suggested that trabectedin dose delays or reductions should be considered before administering prophylactic pegfilgrastim. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- || Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=12, Recruiting, Sponsor: Ossium Health, Inc.
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting
- | Lumakras (sotorasib) / Amgen
Phase classification, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=1143, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Phase classification: P1b/2 --> P1/2
- | Vectibix (panitumumab) / Amgen
Enrollment open, Enrollment change: Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=27, Recruiting, Sponsor: Eben Rosenthal
Phase classification: P1b/2 --> P1/2 Active, not recruiting --> Recruiting | N=15 --> 27
- | Campath (alemtuzumab) / Sanofi, Orencia (abatacept) / BMS, briquilimab (JSP191) / Jasper Therap
New P1/2 trial: Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=72, Not yet recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- || Ovastat (treosulfan) / Medac, Medexus
Trial completion date, Trial primary completion date: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov) - Nov 27, 2023
P2, N=60, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Active, not recruiting --> Recruiting | N=15 --> 27 Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Vectibix (panitumumab) / Amgen
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Panitumumab-IRDye800 in Diagnosing Participants with Malignant Glioma Undergoing Surgery (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=22, Recruiting, Sponsor: Eben Rosenthal
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Recruiting | N=11 --> 22 | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- | Granocyte (lenograstim) / Roche, Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P4 trial: Continuous Versus Bolus Administration of G-CSF in Children With Cancer (clinicaltrials.gov) - Nov 26, 2023
P4, N=40, Recruiting, Sponsor: Chang Gung Memorial Hospital
- | Bay11-7082 / Bayer, SB202190 / Amgen, SP600125 / BMS
Preclinical, Journal: Spring Viremia of Carp Virus Infection Induces Carp IL-10 Expression, Both In Vitro and In Vivo. (Pubmed Central) - Nov 25, 2023
To our knowledge, this is the first time that a fish infection virus upregulated the host IL-10 expression through the JAK-STAT, NF-?B and p38MAPK pathways. Altogether, fish viruses may have a similar mechanism as human or other mammalian viruses to escape host immune surveillance and clearance.
- | Imlygic (talimogene laherparepvec) / Amgen, Vyjuvek (beremagene geperpavec) / Krystal Biotech
Preclinical, Journal, Gene therapy: Attenuated Replication-Competent Herpes Simplex Virus Expressing an ECM-Modifying Transgene Hyaluronan Synthase 2 of Naked Mole Rat in Oncolytic Gene Therapy. (Pubmed Central) - Nov 25, 2023
Another HSV-based drug, beremagene geperpavec (B-VEC), received approval in 2023 to treat the rare genetic disease dystrophic epidermolysis bullosa, and was also the first clinically approved HSV vector carrying an extracellular matrix (ECM)-modifying transgene...The viral replication, transgene expression and cytotoxic effect of the novel vector was studied in glioma cells. Our results show that an attenuated, replication-competent HSV vector expressing a foreign ECM-modifying transgene, namely HAS2, provides an effective tool to study and combat cancer in humans.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal: Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives. (Pubmed Central) - Nov 25, 2023
However, many significant problems are still being experienced with these treatments, mainly off-target effects, toxic side effects, and the associated therapeutic failures of small molecular drugs and the rapid loss of efficacy of mAb therapies. Other novel delivery strategies continue to be investigated, including ligand-based targeting of CRC cells.
- || methotrexate / Generic mfg.
Review, Journal: Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis. (Pubmed Central) - Nov 25, 2023
New game-changing drugs including Mavrilimumab, Iguratimod, Upadacitinib, Fenebrutinib, and nanoparticles may be crucial in controlling symptoms in poorly managed RA patients. Emerging therapeutic targets like Toll-like 4 receptors, NLRP3 inflammasome complexes, and mesenchymal stem cells can further transform RA therapy.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, Metastases: Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative. (Pubmed Central) - Nov 25, 2023
A clinical care pathway focused on the safe provision of denosumab in advanced CKD reduced the risk of hypocalcemia in patients treated in our hospital. Similar pathways could be adopted and tested in other centers.
- | Nplate (romiplostim) / Amgen, Kyowa Kirin, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Journal: HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment. (Pubmed Central) - Nov 25, 2023
Laboratory evaluation revealed a pattern supportive of the clinical impression of HLH, while bone marrow biopsy showed persistent CLL, new reticulin fibrosis, megakaryocytic proliferation, and 32% mutated TET2, but no compelling morphologic evidence of hemophagocytosis. The patient recovered with dexamethasone and g-CSF support.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Reimbursement, US reimbursement, Journal, Medicare: The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare. (Pubmed Central) - Nov 24, 2023
Compared to the pre-COVID period, the lockdown negatively impacted the continuity of romosozumab treatment among Medicare beneficiaries. Prioritizing in-time assistance for patients receiving a provider-administered parenteral therapy is critical when patients' in-person access to their provider is compromised.
- | rocatinlimab (KHK4083) / Kyowa Kirin, Amgen
Journal: Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis. (Pubmed Central) - Nov 23, 2023
Prioritizing in-time assistance for patients receiving a provider-administered parenteral therapy is critical when patients' in-person access to their provider is compromised. No abstract available
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
New trial, Metastases: A single-arm, exploratory clinical study on the treatment of advanced colorectal cancer as third-line and beyond with a standard third-line regimen (TAS102 (EUDRACT) - Nov 22, 2023
P=N/A, N=30, Not yet recruiting, Sponsor: First affiliated hospital of Soochow university
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal, Metastases: Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. (Pubmed Central) - Nov 22, 2023
The common grades 3 and 4 adverse events were diarrhea and neutropenia. Our findings show that triplet-drug chemotherapy (FOLFOXIRI) combined with anti-EGFR antibody (panitumumab or cetuximab) represents a very effective therapeutic combination associated with a significant ORR and R0 rection rate for patients with molecularly unselected and surgically unresectable metastatic CRC.
- | Ibrance (palbociclib) / Pfizer
Journal: CDK4/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence. (Pubmed Central) - Nov 22, 2023
We propose that the levels of p21 integrate signals from overgrowth-triggered stresses to determine cell fate. This model explains how hypertrophy can drive senescence and why CDK4/6 inhibitors have long-lasting effects in patients.
- || Omontys (peginesatide) / Affymax, Krystexxa (pegloticase) / Amgen
Review, Journal: A singlicate immunogenicity method to detect anti-polyethylene glycol antibodies: pre- and post-dose of PEGylated therapies. (Pubmed Central) - Nov 22, 2023
Materials & The repetitive, linear PEG structure prevented the use of a bridging homogenous format, hence the requirement to use a solid phase extraction and acid dissociation assay coupled with the Meso Scale Discovery platform. Results & Using singlicate analysis, the method was validated to successfully detect APA pre- and postdose, with a crucial aspect of the method being the preparation of an appropriate negative control.
- Prolia (denosumab) / Amgen
Trial primary completion date: DEFENCE: Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (clinicaltrials.gov) - Nov 22, 2023
P2, N=8, Active, not recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Results & Using singlicate analysis, the method was validated to successfully detect APA pre- and postdose, with a crucial aspect of the method being the preparation of an appropriate negative control. Trial primary completion date: Jul 2024 --> Sep 2023
- ||| efavaleukin alfa (AMG 592) / Amgen
Phase classification, Trial termination: Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=32, Terminated, Sponsor: Amgen
Trial primary completion date: Jul 2024 --> Sep 2023 Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Sponsor Decision
- | Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Journal: Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto. (Pubmed Central) - Nov 22, 2023
Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Sponsor Decision No abstract available
- | Trial completion date, Trial initiation date, Trial primary completion date: Application of N-of-1 Rheumatoid Arthritis (clinicaltrials.gov) - Nov 22, 2023
P=N/A, N=18, Not yet recruiting, Sponsor: Tufts Medical Center
No abstract available Trial completion date: Oct 2025 --> Jan 2025 | Initiation date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2024 --> Jan 2025
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: In severe, uncontrolled asthma, tezepelumab reduced exacerbations over 1 y regardless of type 2 inflammation level. (Pubmed Central) - Nov 22, 2023
2023;208:13-24. 37015033.